
Two newly initiated phase 2/3 studies will spell extra profit for ALK-Abello. The Danish pharmaceutical group’s Japanese partner has begun concluding clinical trials with the pill Mitizax against hay fever and asthma caused by house dust mites.
As soon as the first trial person is given the medicine it triggers a non-disclosed milestone payment for ALK-Abello, however, as it is expected and therefore already included in the finances, it does not change the company’s expectations for 2012.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app